Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Obesity Right
  3. Foundayo (orforglipron) tablet Right
  4. Can patients taking Foundayo™ (orforglipron) have grapefruit?
Search Foundayo (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Foundayo ™ (orforglipron) tablet

0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

Can patients taking Foundayo™ (orforglipron) have grapefruit?

There is no information related to drug interaction between orforglipron and grapefruit included in the prescribing information.

US_cFAQ_OFG409_USE_WITH_GRAPEFRUIT_T2D_WM
US_cFAQ_OFG409_USE_WITH_GRAPEFRUIT_T2D_WMen-US

See important safety information, including boxed warning, in the attached prescribing information.

Does Grapefruit Interact With Orforglipron?

Orforglipron is metabolized primarily via hepatic cytochrome P3A4 (CYP3A4) to several oxidative metabolites.1

Grapefruit juice is a potent inhibitor of intestinal CYP3A4 and is considered to be a moderate inhibitor by the FDA due to its variable systemic exposure. It contains furanocoumarins that cause inhibition of intestinal CYP3A4. It does not meaningfully inhibit hepatic CYP3A4 at dietary exposures.2-4

Therefore, eating grapefruit or drinking grapefruit juice is not included in the Foundayo prescribing information related to drug interactions.1

Enclosed Prescribing Information

FOUNDAYO™ (orforglipron) tablets, for oral use, Lilly

References

1Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.

2US Food and Drug Administration. For healthcare professionals: FDA's examples of drugs that interact with CYP enzymes and transporter systems. Accessed April 2, 2026. https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems

3Kane G and Lipsky J. Drug–grapefruit juice interactions. Mayo Clin Proc. 2000;75(9):933-942. https://doi.org/10.4065/75.9.933

4Dayyih WA, Al-Ani I, Hailat M, et al. Review of grapefruit juice-drugs interactions mediated by intestinal CYP3A4 inhibition. J Appl Pharm Sci. 2024;14(5):59-68. https://dx.doi.org/10.7324/JAPS.2024.160197

Date of Last Review: April 01, 2026

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.53 05/2026 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2026. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly